この記事を読む

オシメルチニブ心毒性のリスク因子

The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population. Bak M et al.J Thorac Oncol.…

この記事を読む

PD後の免疫療法継続の利益はmGPSで分かる?

The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression. Saal J …

この記事を読む

「ドライバー変異なし」でもCGP検査で25%に標的遺伝子変異が見つかる

Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database…

この記事を読む

大規模臨床試験データでのLIPIの有用性の検証

Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc …

この記事を読む

抗PD-1抗体無効後のPD-L1抗体:アテゾリズマブ投与

Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Dire…

この記事を読む

分子標的治療後の有望な選択肢:ダトポタマブ デルクステカン

Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results…

この記事を読む

POSEIDON試験の5年生存率、KEAP1/STK11+に活路?

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overa…

この記事を読む

LAURA試験でのオシメルチニブの中枢神経系再発への抑制効果

Osimertinib after definitive chemoradiotherapy in unresectable stageⅢ epidermal growth factor receptor-mutated non-small…

この記事を読む

オシメルチニブのbeyond-PD投与

The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastati…

この記事を読む

エヌトレクチニブとクリゾチニブの疑似比較

Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indir…